Abstract
New chemical entities are routinely screened in vitro and in vivo for their ability to induce cytochrome P450s (CYP), other drug-metabolizing enzymes and possibly transporters in an attempt to more accurately predict clinical parameters such as drug-drug interactions and clearance in humans. Some of these potential therapeutic agents can cause induction of the metabolism of another molecule or auto-induction thereby increasing their own metabolism and elimination, as well as potentially any molecules metabolized by the same enzyme(s). Key CYPs in the 1A, 2B, 2C, and 3A families have all been shown to be inducible. It would be clearly advantageous to know the potential for a compound to induce drug metabolizing enzymes or transporters prior to clinical development, and many in vitro systems have been developed for this purpose. Newer computational technologies are also being applied in order to attempt to predict induction from the molecular structure alone before a molecule is even synthesized or tested. This review will cover the various in vitro and in silico methods developed for prediction of key inducers of CYPs and other proteins, as well as the limitations of such technologies and applications in the future.
Keywords: Cytochrome P450,, induction,, pharmacophore,, QSAR,, PXR,, CAR,, GR,, VDR.
Current Drug Metabolism
Title: Prediction of Human Drug Metabolizing Enzyme Induction
Volume: 4 Issue: 5
Author(s): Dayna C. Mankowski and Sean Ekins
Affiliation:
Keywords: Cytochrome P450,, induction,, pharmacophore,, QSAR,, PXR,, CAR,, GR,, VDR.
Abstract: New chemical entities are routinely screened in vitro and in vivo for their ability to induce cytochrome P450s (CYP), other drug-metabolizing enzymes and possibly transporters in an attempt to more accurately predict clinical parameters such as drug-drug interactions and clearance in humans. Some of these potential therapeutic agents can cause induction of the metabolism of another molecule or auto-induction thereby increasing their own metabolism and elimination, as well as potentially any molecules metabolized by the same enzyme(s). Key CYPs in the 1A, 2B, 2C, and 3A families have all been shown to be inducible. It would be clearly advantageous to know the potential for a compound to induce drug metabolizing enzymes or transporters prior to clinical development, and many in vitro systems have been developed for this purpose. Newer computational technologies are also being applied in order to attempt to predict induction from the molecular structure alone before a molecule is even synthesized or tested. This review will cover the various in vitro and in silico methods developed for prediction of key inducers of CYPs and other proteins, as well as the limitations of such technologies and applications in the future.
Export Options
About this article
Cite this article as:
Mankowski C. Dayna and Ekins Sean, Prediction of Human Drug Metabolizing Enzyme Induction, Current Drug Metabolism 2003; 4 (5) . https://dx.doi.org/10.2174/1389200033489352
DOI https://dx.doi.org/10.2174/1389200033489352 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Pathobiology of Head and Neck Squamous Tumorigenesis
Current Cancer Drug Targets Non-Analgesic Effects of Opioids: Mechanisms and Potential Clinical Relevance of Opioid-Induced Immunodepression
Current Pharmaceutical Design The Mechanism of Action of Salsolinol in Brain: Implications in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Microencapsulation: The Emerging Role of Microfluidics
Micro and Nanosystems Performance and Effect of Automatic Contouring in Automatic Adaptive Planning for Prostate Cancer Volumetric Modulated Radiotherapy
Recent Patents and Topics on Imaging (Discontinued) Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents
Current Medicinal Chemistry Vitamin D Represses the Aggressive Potential of Osteosarcoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Can We Predict the Sites of the Recurrence of Ovarian Cancer by F-18 FDG PET/CT Depending on CA-125 Level?
Current Medical Imaging The Etiology of Hypertension in the Metabolic Syndrome Part Four: The Systemic Perspective – The Role of the Neuroendocrine and Immune Systems,and the Challenge of Integration
Current Vascular Pharmacology Ghrelin in Obesity, Physiological and Pharmacological Considerations
Mini-Reviews in Medicinal Chemistry Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging Antiangiogenic Function of Antithrombin is Dependent on its Conformational Variation: Implication for Other Serpins
Protein & Peptide Letters Environmental Factors and Hypertension
Current Pharmaceutical Design